PET scan for cardiac amyloidosis after inconclusive tests
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure or carry the TTR gene mutation, even if you have no symptoms.
- A prior heart scan could not clearly show ATTR-CA (a type of amyloid buildup in the heart).
- Your TAD1 blood test level is elevated (a marker of amyloid protein).
- You do not have amyloid caused by other conditions (AL or AA).
- You are not on kidney dialysis, not taking heparin, and not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This study tests a new PET imaging agent that may help doctors see amyloid buildup in the heart more clearly. It may help people with heart amyloidosis or those suspected of having it.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.